NCT05130515View on ClinicalTrials.gov

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Interventions
DRUG

Niraparib

Niraparib 200mg po QD, day1\~21

DRUG

Anlotinib

Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle

Trial Locations (1)

510000

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER